Scadding' defined fibrosing alveolitis as a disorder of the lower respiratory tract characterised by inflammation and fibrosis of the pulmonary interstitium and peripheral airspaces. This leads to derangement of the alveolar wall and loss of functional alveolar capillary units, resulting in a restrictive pattern in lung function tests.
The term has been used to describe a large number ofpulmonary diseases, including those caused by inhaled dusts, such as asbestos, or the administration of drugs such as amiodarone, gold, busulphan, and bleomycin or those associated with collagen vascular diseases, such as rheumatoid arthritis and systemic sclerosis. In three quarters of cases, however, no causative agent or associated condition can be found and these are referred to as cryptogenic fibrosing alveolitis (TurnerWarwick et al2) to emphasise both the inflammatory and the fibrotic components of the disease. In the United States the condition is referred to as idiopathic pulmonary fibrosis. Its prevalence in the United Kingdom is five cases per 100 000 of the population3 and mortality is increasing, 1200-1400 people dying each year from the condition. 4 
Aetiology
Many studies, particularly in animals exposed to toxic agents such as bleomycin5 or asbestos,6 support the idea that direct injury to capillarỹ~~9 endothelial cells, shared basement membrane, and pneumocyte.type 1 epithelial cells leads to interstitial fibrosis. Furthermore, in the adult respiratory distress syndrome acute lung injury results in similar damage and survivors often develop diffuse interstitial fibrosis. 7 Injury is believed to be due either to inhalation of injurious agents or to blood borne agents. Many consider that viral infections play a part but this has never been proved. Only one study, of 13 patients, has found serum antibodies to Epstein-Barr virus but the meaning of this remains unclear. 8 Occupational or environmental exposure could be relevant. Recent work has suggested that exposure to metal dust and wood fires may have a role. 9 In general, the initiating agent or agents in fibrosing alveolitis remain unknown.
Epithelial and endothelial cell injury Most current theories on the pathogenesis of pulmonary fibrosis are based on the hypothesis that there is initial damage to endothelial or epithelial cells or both. Inflammatory and immune cells then move into the interstitium and alveolar spaces from the circulation and release mediators that stimulate collagen production by fibroblasts.'0 In fibrosing alveolitis and asbestosis there is ultrastructural evidence of both epithelial and endothelial cell injury from the earliest stages of disease. 6 The injury and loss of these cells can affect the underlying tissues.
Epithelial control of fibroblast proliferation has been seen in tracheal grafts. If 
NEUTROPHILS
Infiltration of the lungs by neutrophils is an early event in animal models of lung injury induced by bleomycin and asbestos.' Neutrophils migrate into tissue after adhering to endothelial cells by expressing cell surface adhesion molecules, particularly the integrin CD18/CD1 ib, which acts as a ligand for the intercellular adhesion molecule (ICAM)-1. In addition, endothelium produces endothelial leucocyte adhesion molecules (ELAM)-1, which serve to bind neutrophils, and this secretion is enhanced by the cytokines interferon y, tumour necrosis factor (TNF)-cx, and interleukin (IL)-1.20 Neutrophils release a wide range of granule associated enzymes, particularly proteases and collagenases, which can degrade the connective tissue matrix.2' They also release highly reactive oxygen radicals such as superoxide anion, hydrogen peroxide, hydroxyl radicals, and hypohalous acids, which can cause epithelial cell injury.2' 22 These oxygen radicals require myeloperoxidase, a granule protein found in neutrophils, and halide anions for their production. Glutathione, which is a powerful oxygen radical scavenger, is present in large amounts in the normal respiratory tract and protects the respiratory epithelium from damage. 23 There is a reduction in glutathione in the lower respiratory tract of patients with fibrosing alveolitis, which could exaggerate the effects of oxygen radicals. 24 Although few neutrophils are observed within the lung interstitium in fibrosing alveolitis, their number is increased in lavage fluid, suggesting that they rapidly traffic out of the capillaries into the airspaces. In patients at risk of developing fibrosing alveolitis, such as those with systemic sclerosis or rheumatoid arthritis, neutrophils are increased in lavage fluid in the absence of radiological evidence of lung disease, indicating subclinical alveolitis. ' The neutrophil chemotactic factors include a 400-600 Da factor, which is produced by macrophages that have been stimulated by immune complexes or lavage fluid containing immune complexes.47 A second 10 000 Da moiety is produced when macrophages are stimulated by IgG or zymogen particles. There is evidence that IL-8 is a component of this moiety." IL-8 is one of at least 10 8-10 kDa proteins that form the recently defined intercrine supergene family49 and is a potent neutrophil chemoattractant and activator, which can be synthesised by many cells, including fibroblasts, epithelial cells, and macrophages.50 51 There is some evidence that the cytokines TNF-a and IL-1 are produced by alveolar macrophages derived from patients with fibrosing alveolitis.525' TNF-a can have an autocrine stimulatory effect on macrophages and can also influence other inflammatory cells, such as neutrophils and lymphocytes. 54 Further work needs to be done to clarify the expression and regulation of cytokines and adhesion molecules in fibrosing alveolitis.
Macrophages release several mediators that can stimulate lung fibroblast proliferation. Of these, fibronectin, platelet derived growth factor (PDGF), and insulin like growth factor 1 (IGF-1) have been implicated in the pathogenesis of fibrosing alveolitis and will be discussed in more detail below. The mechanism for the recruitment of lymphocytes in fibrosing alveolitis remains unclear. One possibility is that activated lung fibroblasts play a part. Fibroblasts have been shown to produce large amounts of two inflammatory mediators IL-6 and IGF-1, which have potent effects on lymphocyte chemotaxis and mitosis.67 Further studies are needed before firm conclusions about the role of lymphocytes in the pathogenesis of fibrosing alveolitis can be reached.
LYMPHOCYTES

Activation of lung fibroblasts
There are several potential mechanisms for fibroblast activation in the lung6 69: firstly, an increase in fibroblast number, occurring as a result of either fibroblast proliferation or recruitment offibroblasts from undifferentiated stem cells or by chemoattraction of cells from adjacent areas; secondly, increased collagen biosynthesis; and, thirdly, diminished collagen degradation, either through a reduction in the rate at which newly synthesised procollagens are degraded or by reduced enzymatic breakdown of collagens in the extracellular matrix. Each of these mechanisms will be discussed below. FIBROBLAST PROLIFERATION Evidence that fibroblast proliferation is an important mechanism in the pathogenesis of fibrosing alveolitis is based on two lines of evidence. Firstly, morphological studies have shown that fibroblast numbers are increased. 70 Secondly, alveolar macrophages from patients with fibrosing alveolitis spontaneously release fibroblast mitogens when cultured in vitro.7' Current theories of cell division propose that two different kinds of signal (called competence and progression factors) are required for mitosis to occur.72 These signals are thought to act at different stages of the cell cycle (fig 3) .
Fibronectin is an important adhesive molecule in the extracellular matrix. It can also act as a chemoattractant for fibroblasts and as a competence factor, inducing cells in the G phase of the cell cycle to enter GI. Macrophages are known to infiltrate the lungs of patients with pulmonary fibrosis and spontaneously secrete more fibronectin than macrophages derived from healthy lung.7374 Consequently, it has been proposed that macrophage derived fibronectin may have a role in the pathogenesis of fibrosing lung disease.
The Attempts to quantify production rates of IGF-1 like molecules by macrophages in cell culture have met with difficulties because of the presence of binding proteins,85 but the amount produced by alveolar macrophages may be small compared with that from other potential sources.
The ease by which alveolar macrophages can be obtained by the technique of bronchoalveolar lavage may have led to an exaggerated view of the importance of this cell in the pathogenesis of pulmonary fibrosis. We do not know whether the alveolar macrophages are capable of producing sufficient quantities of growth factors (both in terms of absolute quantities and because their bioavailability may be affected by the presence of binding proteins) to activate interstitial fibroblasts in vivo.
For a balanced view of the pathogenesis of fibrosing alveolitis we must consider the possibility that mediators from sources other than the alveolar macrophage will affect lung fibroblasts. Selman and coworkers86 showed that T lymphocytes from the lungs of patients with cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis released a mediator that inhibited fibroblast proliferation. By contrast, circulating T lymphocytes from the same patients and from controls released a mediator that caused modest stimulation of fibroblast proliferation, confirming a similar observation from an earlier study.87 These findings indicate differences in behaviour between lung and blood lymphocytes and illustrate the danger of drawing generalised conclusions about lung lymphocytes from studies of cells derived from the circulation. They also support the observations discussed earlier that lymphocytes have an antifibrotic effect in animal models of pulmonary fibrosis.
Attempts to isolate mediators from purified preparations of individual cell types cultured in vitro may also give a misleading impression of their importance as activators of lung fibroblasts in vivo. Cantin and coworkers88 determined the overall effect of lavage concentrates on human fibroblasts. This approach permits the combined effects of mediators present in vivo to be assessed but it does not permit their source to be identified. They found that lavage fluid from patients with fibrosing alveolitis stimulated significantly more uptake of thymidine by fibroblasts than did controls, suggesting that it contained fibroblast growth factors. Furthermore, this stimulatory activity was correlated with indices of lung collagen production in vivo.
Alternative hypotheses have been proposed to explain the observed increase in fibroblast numbers in patients with pulmonary fibrosis.
Jordana and colleagues89 showed that fibroblasts derived from fibrotic lung tissue proliferate significantly faster than controls when cultured in vitro. They observed a pronounced heterogeneity in the proliferative characteristics of lung fibroblasts, with certain clone derived cell lines showing a "fast replicating" phenotype, and proposed that the conditions of injury and repair prevailing in the lower respiratory tract might select out fast replicating fibroblast clones. In a similar study Raghu and As procollagen molecules are secreted from cells the procollagen peptides are cleaved by proteases, which are specific for either the N or the C terminal ends, but not for each collagen type. Several biological functions have been ascribed to these so called procollagen peptides. Before secretion they are thought to prevent premature fibril formation but after secretion may direct fibril assembly. Cleavage of the C terminal propeptide has been shown to be the rate controlling step for assembly of type I fibrils in vitro. 94 The N terminal propeptides of collagen types I and III have been shown to exert a negative feedback on collagen synthesis by fibroblasts cultured in vitro. 95 Procollagen peptides have recently assumed clinical importance as potential markers of collagen production in vivo. Several features make them useful for this purpose. They are thought to be released in stoichiometric amounts when collagen molecules are secreted from cells; they are immunologically distinct for each collagen type; and their high carbohydrate content renders them antigenic. Consequently, radioimmunoassays that detect procollagen peptides in biological fluids have been developed and several are commercially available. Most widely used are assays which measure the N terminal propeptide of type III collagen. Increased concentrations of type III procollagen N terminal peptides have been detected in the serum of patients with various fibroproliferative disorders,96 and these assays have also been applied to bronchoalveolar lavage fluid from patients with pulmonary fibrosis.97 Two areas of research have been important in improving our understanding of the regulation of lung collagen production. These are the development of molecular biological techniques that permit the investigation of elements regulating collagen gene expression, and the discovery and characterisation of polypeptide mediators that have potent effects on the mesenchymal cells producing collagen.
One such mediator is transforming growth factor # (TGF-/3), a 25 kDa dimeric peptide composed of two identical disulphide bonded subunits, which occurs in at least five different isoforms. TGF-,B was originally purified from human platelets, human placenta, and bovine kidney but is widely distributed throughout the animal kingdom, being totally conserved in human, bovine, and porcine species.98 TGF-# turnover is most rapid for collagens soluble in solutions of low ionic strength (that is, those most recently synthesised). Secondly, experiments by Barnes and coworkers'09 show the rapid appearance of radiolabelled hydroxyproline after the injection of radiolabelled proline into guinea pigs. As hydroxylation of proline occurs as a post-translation event during procollagen synthesis, this observation suggests that the radiolabelled hydroxyproline is derived from the degradation of a larger substrate molecule. Bienkowski and coworkers"0 consider that the substrate is most likely to be procollagen and that degradation occurs intracellularly by proteases located in the endoplasmic reticulum or Golgi apparatus."'
Rates of intracellular degradation of procollagen are known to increase in response to agents that inhibit the hydroxylation of proline."2 This "enhanced degradation," defined by Bienkowski"' as an increase above basal concentrations, can be blocked by inhibitors of lysosomal proteases and by colchicine. It can also be increased by PGE2 and epidermal growth factor,"13 and this represents a potential site at which procollagen may be regulated.
EXTRACELLULAR MECHANISMS
The extracellular degradation of collagen is thought to result largely from the action of neutral proteases. Fibroblasts actively produce collagenase, gelatinase, and stromelysin, enzymes that cleave collagen or its breakdown products."' Leucocytes also produce collagenases, which may contribute to remodelling of lung extracellular matrix in disease states.
Neutrophil collagenase, a metalloproteinase found preformed in neutrophil specific granules, is one such protease. It is produced in latent form and activated extracellularly. Mast/el also possess a gelatinase capable of degrading collagen. 6 Macrophages secrete both collagenase and stromelysin and these have properties identical to those of the enzymes produced by fibroblasts. They also produce a gelatinase that is immunologically identical to neutrophil gelatinase. In the circulation collagenases are inhibited by x2 macroglobulin and #f anticollagenase and in tissues by the tissue inhibitor of metalloproteinases. The latter is produced by fibroblasts"7 and represents another site at which collagen deposition could be regulated.
The relevance of changes in rates of collagen degradation to the pathogenesis of pulmonary fibrosis has received relatively little attention. It has been reported that a reduction in the degradation of newly synthesised collagen contributes to the development of bleomycin induced pulmonary fibrosis in rabbits."8 There is also evidence that the increase in procollagen production induced by TGF-,B in rat fetal fibroblasts is associated with a reduction in the rate at which newly synthesised procollagen is degraded. l' Role ofepithelial and endothelial barriers As described earlier in this review, injury to pulmonary endothelial and epithelial cells is known to occur in pulmonary fibrosis '23 and to enhance lung fibroblast proliferation in bleomycin induced pulmonary fibrosis in animals.'24 Fibrin can act as a matrix on which fibroblasts may grow'25 and the soluble products of clot formation are known to act as chemoattractants for fibroblasts'26 and to stimulate human lung fibroblast proliferation. 123 Characterised growth factors for fibroblasts, such as fibronectin, platelet derived growth factor, and IGF-1, are all present in blood and are known to be partly responsible for the stimulatory effects ofserum on fibroblast proliferation and collagen production. '27 Taken together, these data provide compelling evidence that pulmonary vascular leakage of proteins may activate lung fibroblasts and initiate deposition of collagen in the lung interstitium.
The fibroblast as an effector cell Lung fibroblasts are not simply target cells that respond to inflammatory mediators in their environment. They are increasingly recognised as effector cells in their own right.' Their ability to produce fibronectin and an IGF-1 like molecule was discussed earlier in this article. They also secrete PGE2, which has potent paracrine and autocrine effects inhibiting fibroblast proliferation and collagen synthesis. 129 There is also evidence that fibroblasts can amplify the production of mediators produced by other cells. Lung fibroblasts are capable of secreting IL-1 in response to the synergistic actions of IL-I and TNFx.'30 Thus the production of IL-1 by fibroblasts may represent an amplification mechanism for this inflammatory mediator that can stimulate fibroblast collagen production."
Fibroblasts also produce IL-6, also called interleukin /2, which stimulates lymphocyte proliferation and induces release of acute phase proteins from the liver.'3' Possibly therefore IL-6 secreted by lung fibroblasts stimulates lymphocyte proliferation in the lung and is responsible, at least in part, for the systemic symptoms of which patients with interstitial lung disease frequently complain, particularly in the early stages.
Human lung fibroblasts have also been shown to spontaneously release granulocytemacrophage colony stimulating factor, which enhances in vitro survival of eosinophils. '32 This suggests that they have the potential to modulate the inflammatory cell population that infiltrates the lung. Preliminary studies indicate that rat lung fibroblasts are capable of producing both platelet derived growth factor like molecules'33 and TGF-# analogues, ' 
